The rare disease clinical trials market size is projected to be valued at US$ 12,566.14 million in 2023 and is expected to rise to US$ 31,715.25 million by 2033. The sales of rare disease clinical trials are expected to record a significant CAGR of 9.7% during the forecast period.
Various Factors Propelling the Demand for Rare Disease Clinical Trials
The rare disease clinical trials market refers to the development of drugs and therapies for the treatment of rare diseases. These diseases, by definition, affect a small percentage of the population. Consequently, there is often limited research and development in this area.
Clinical trials for rare diseases can be challenging due to the small patient population, limited natural history data, and a lack of standardized endpoints. However, the market is growing due to increased funding and attention to the development of treatments for these diseases.
For example, The Orphan Drug Act was passed in the United States in 1983. The act was enacted to offer financial incentives to pharmaceutical companies to develop treatments for rare diseases.
The advancement in technology and genomics allows for more targeted treatments and personalized medicine. Additionally, there has been increased collaboration between patient advocacy groups, researchers, and the industry. This collaboration has helped to overcome some challenges of conducting clinical trials in rare diseases.
Overall, the market represents an important area of research and development. As it offers hope for patients with conditions that may have previously been considered untreatable.
| Attribute | Details |
|---|---|
| Rare Disease Clinical Trials Market Estimated Size (2023) | US$ 12,566.14 million |
| Rare Disease Clinical Trials Market CAGR (2023 to 2033) | 9.7% |
| Rare Disease Clinical Trials Market Forecasted Size (2033) | US$ 31,715.25 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rare disease clinical trials market was valued at US$ 11,455.0 million in 2022 with a substantial growth trajectory of 8.9% between the analysis period of 2018 to 2022.
Future Market Insights expects the rare disease clinical trials market to expand at a CAGR of 9.7% during the forecast period of 2023 to 2033. The growth can be attributed to the following reasons
Considering the above-mentioned factors, FMI opines, the rare disease clinical trials market is likely to witness a market value of US$ 31,715.25 million by the end of 2033.
Principal Consultant
Rare Disease Clinical Trials Market:
| Attributes | Rare Disease Clinical Trials Market |
|---|---|
| CAGR (2023 to 2033) | 9.7% |
| Market Value (2023) | US$ 12,566.14 million |
| Growth Factor | The scarcity of drugs for treating rare diseases, advances in personalized medicine, and cell and gene therapies. All these factors are opening up new avenues for the development of new treatments for rare diseases. |
| Opportunity | An increase in funding for rare disease clinical trials from pharmaceutical and biotech companies, as well as non-profit organizations, is further supporting market growth. |
Rare Inflammatory Disease Treatment Market:
| Attributes | Rare Inflammatory Disease Treatment Market |
|---|---|
| CAGR (2023 to 2033) | 4.6% |
| Market Value (2023) | US$ 17,335.8 million |
| Growth Factor | Increased investment in research and development for various drug developments. Additionally, growing demand for various modes of drug administration, have increased market demand. |
| Opportunity | Increased investment in R&D for various drug developments. Increased demand for various modes of drug administration has boosted market demand for various rare inflammatory disease treatments. |
Infectious Disease Diagnostics Market:
| Attributes | Infectious Disease Diagnostics Market |
|---|---|
| CAGR (2023 to 2033) | 7.0% |
| Market Value (2023) | US$ 3.48 billion |
| Growth Factor | Diagnosis is the first and most important step in identifying and treating an illness. Scientific advances are transforming the practice of performing quick diagnostics. Ongoing technological breakthroughs might continue to alter the industrial environment during the forecast period. |
| Opportunity | Several government-funded initiatives are gradually offering free screening and testing all over the world. To raise awareness, properly diagnose illnesses, and reduce the risk of infection. |
In 2022, the oncology segment held a notable share of 33.9%. A few of the key factors fueling the segment growth are
For example, in January 2023, the USFDA approved atezolizumab (Tecentriq), an immunotherapy drug for advanced alveolar soft part sarcoma patients (ASPS).
During the forecast period, the infectious disease segment is expected to expand at an exponential rate of 10.6%. Acanthamoeba keratitis, Q fever, Marburg virus, and other rare infectious diseases are examples. As these rare diseases are fatal, researchers are hugely interested in developing treatments and vaccines for them. Contact lens wearers are likely to develop Acanthamoeba keratitis. Over 85% of people in the United States wear contact lenses. This increases the risk of disease and fuels the demand for treatment. These factors are assisting segment growth.
In 2022, Phase II had a notable share of 42.6%. Phase II studies are divided into two parts: the first part includes dose range exploration as well as efficacy studies, while the second part includes dose finalization. Over 100-300 participants are recruited for Phase II clinical trials. The phase II segment had the most registered clinical studies as of November 2022. The ClinicalTrial.gov portal had 72,522 studies registered as of November 2022. The high amount of Phase II clinical trials is driving the segment's growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The United States has a well-established regulatory framework for rare disease clinical trials, with the Orphan Drug Act of 1983. It provides incentives for the development of drugs for rare diseases. The FDA's Breakthrough Therapy Designation program has also facilitated the development of drugs for rare diseases. Additionally, the National Institutes of Health (NIH) has established a Rare Diseases Clinical Research Network (RDCRN) to facilitate the conduct of clinical trials for rare diseases.
Europe is a significant market for rare disease clinical trials, with countries like Germany, France, and the United Kingdom accounting for a significant share of the market. The European Medicines Agency (EMA) has been proactive in offering regulatory support for rare disease drug development. Therefore, the support from several agencies has increased the clinical trials in Europe.
Asia Pacific is a significantly growing market for rare disease clinical trials, with countries like China, Japan, and India emerging as key players. The region offers a substantial patient population and low trial costs compared to Western countries. Making it an attractive destination for colossal clinical trials. However, the regulatory environment in some countries can be challenging, and there is a need for great awareness and education about rare diseases.
Latin America is an emerging market for rare disease clinical trials, with countries like Brazil and Mexico. The region offers a diverse patient population and low trial costs compared to North America and Europe. However, there are challenges in terms of regulatory compliance and infrastructure, which can limit the growth of the market.
The Middle East and Africa region is a small but growing market for rare disease clinical trials. Countries like South Africa and Israel are emerging as key players due to their advanced healthcare infrastructure and supportive regulatory environment. However, there are challenges related to political instability, low awareness about rare diseases, and limited healthcare resources in some parts of the region.
The rare disease clinical trials market is highly competitive, with several global players operating in the space. Some key players in the market include
In addition to these companies, there are many other small CROs and specialized service providers operating in the rare disease clinical trials market. As the market continues to grow, competition among these companies is expected to increase. These players are competing on factors such as service quality, expertise, and pricing.
| Attribute | Details |
|---|---|
| Growth Rate | CAGR of 9.7% from 2023 to 2033 |
| Base Year of Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and Volume in Units and F-CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis |
| Key Segments Covered | By Therapeutic Area, By Sponsor, By Phases, By Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; The Middle East & Africa;Oceania |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, Italy, France, The United Kingdom, Spain, Russia, China, Japan, India, GCC Countries, Australia |
| Key Companies Profiled | Takeda Pharmaceutical Company; F. Hoffmann-La Roche Ltd.; Pfizer, Inc.; AstraZeneca; Novartis AG; LabCorp; IQVIA, Inc.; Charles River Laboratories; Icon PLC; Parexel International Corporation |
| Customization & Pricing | Available upon Request |
The market is valued at US$ 12.5 billion in 2023.
Pfizer, Inc., AstraZeneca, and Novartis AG are the top market players.
The market held a CAGR of 8.9% from 2018 to 2022.
Advancements in personalized medicine to boost market growth.
Phase II segment is likely to remain preferred through 2033.
1. Executive Summary | Rare Disease Clinical Trials Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033 5.3.1. Oncology 5.3.2. Cardiovascular Disorders 5.3.3. Neurological Disorders 5.3.4. Infectious Disease 5.3.5. Genetic Disorders 5.3.6. Autoimmune And Inflammation 5.3.7. Hematologic Disorders 5.3.8. Musculoskeletal Disorders 5.3.9. Others 5.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Phase 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Phase, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Phase, 2023 to 2033 6.3.1. Phase I 6.3.2. Phase II 6.3.3. Phase III 6.3.4. Phase IV 6.4. Y-o-Y Growth Trend Analysis By Phase, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Phase, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sponsor 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Sponsor, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sponsor, 2023 to 2033 7.3.1. Pharmaceutical & Biopharmaceutical Companies 7.3.2. Non-profit Organizations 7.4. Y-o-Y Growth Trend Analysis By Sponsor, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Sponsor, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Therapeutic Area 9.2.3. By Phase 9.2.4. By Sponsor 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Therapeutic Area 9.3.3. By Phase 9.3.4. By Sponsor 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Therapeutic Area 10.2.3. By Phase 10.2.4. By Sponsor 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapeutic Area 10.3.3. By Phase 10.3.4. By Sponsor 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Therapeutic Area 11.2.3. By Phase 11.2.4. By Sponsor 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapeutic Area 11.3.3. By Phase 11.3.4. By Sponsor 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Therapeutic Area 12.2.3. By Phase 12.2.4. By Sponsor 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapeutic Area 12.3.3. By Phase 12.3.4. By Sponsor 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Therapeutic Area 13.2.3. By Phase 13.2.4. By Sponsor 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapeutic Area 13.3.3. By Phase 13.3.4. By Sponsor 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Therapeutic Area 14.2.3. By Phase 14.2.4. By Sponsor 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapeutic Area 14.3.3. By Phase 14.3.4. By Sponsor 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Therapeutic Area 15.2.3. By Phase 15.2.4. By Sponsor 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Therapeutic Area 15.3.3. By Phase 15.3.4. By Sponsor 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Therapeutic Area 16.1.2.2. By Phase 16.1.2.3. By Sponsor 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Therapeutic Area 16.2.2.2. By Phase 16.2.2.3. By Sponsor 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Therapeutic Area 16.3.2.2. By Phase 16.3.2.3. By Sponsor 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Therapeutic Area 16.4.2.2. By Phase 16.4.2.3. By Sponsor 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Therapeutic Area 16.5.2.2. By Phase 16.5.2.3. By Sponsor 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Therapeutic Area 16.6.2.2. By Phase 16.6.2.3. By Sponsor 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Therapeutic Area 16.7.2.2. By Phase 16.7.2.3. By Sponsor 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Therapeutic Area 16.8.2.2. By Phase 16.8.2.3. By Sponsor 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Therapeutic Area 16.9.2.2. By Phase 16.9.2.3. By Sponsor 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Therapeutic Area 16.10.2.2. By Phase 16.10.2.3. By Sponsor 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Therapeutic Area 16.11.2.2. By Phase 16.11.2.3. By Sponsor 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Therapeutic Area 16.12.2.2. By Phase 16.12.2.3. By Sponsor 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Therapeutic Area 16.13.2.2. By Phase 16.13.2.3. By Sponsor 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Therapeutic Area 16.14.2.2. By Phase 16.14.2.3. By Sponsor 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Therapeutic Area 16.15.2.2. By Phase 16.15.2.3. By Sponsor 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Therapeutic Area 16.16.2.2. By Phase 16.16.2.3. By Sponsor 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Therapeutic Area 16.17.2.2. By Phase 16.17.2.3. By Sponsor 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Therapeutic Area 16.18.2.2. By Phase 16.18.2.3. By Sponsor 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Therapeutic Area 16.19.2.2. By Phase 16.19.2.3. By Sponsor 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Therapeutic Area 16.20.2.2. By Phase 16.20.2.3. By Sponsor 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Therapeutic Area 16.21.2.2. By Phase 16.21.2.3. By Sponsor 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Therapeutic Area 17.3.3. By Phase 17.3.4. By Sponsor 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Takeda Pharmaceutical Company 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. F. Hoffmann-La Roche Ltd. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Pfizer, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. AstraZeneca 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novartis AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. LabCorp 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. IQVIA 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Charles River Laboratories Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Icon PLC 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Parexel International Corporation 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
November 2022
REP-GB-15802
250 pages
Explore Healthcare Insights
View Reports
Rare Disease Clinical Trials Market
